|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 12.17 USD | +7.32% |
|
+16.02% | +222.81% |
| 09-25 | SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer | CI |
| 09-14 | Top Premarket Decliners | MT |
Company Valuation: SELLAS Life Sciences Group, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 87.85 | 48.59 | 33.99 | 73.2 | 537 | 2,290 | - | - |
| Change | - | -44.69% | -30.05% | 115.37% | 633.64% | 326.45% | - | - |
| Enterprise Value (EV) | 87.85 | 48.59 | 33.99 | 73.2 | 537 | 2,290 | 2,290 | 2,290 |
| Change | - | -44.69% | -30.05% | 115.37% | 633.64% | 326.45% | 0% | 0% |
| P/E | -4.13x | -1.11x | -0.79x | -2.08x | -15.1x | -55.3x | -119x | 324x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | 0x | 0.3x | 3.1x | 2.2x | -2x |
| Capitalization / Revenue | 11.6x | 48.6x | - | - | - | - | 43.1x | 18.8x |
| EV / Revenue | 0x | 0x | - | - | - | - | 43.1x | 18.8x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -56.1x | -89.9x | -701x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.34 | -2.13 | -1.34 | -0.5 | -0.25 | -0.205 | -0.095 | 0.035 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.6 | 1 | - | - | - | - | 53.09 | 122 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -25.29 | -41.95 | -37.87 | -31.51 | -28.27 | -40.79 | -25.48 | -3.266 |
| Net income 1 | -20.7 | -41.3 | -37.34 | -30.88 | -26.86 | -38.3 | -21.38 | 2.984 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 5.53 | 2.36 | 1.06 | 1.04 | 3.77 | 11.34 | 11.34 | 11.34 |
| Nbr of stocks (in thousands) | 15,886 | 20,588 | 32,062 | 70,382 | 142,442 | 201,946 | - | - |
| Announcement Date | 3/31/22 | 3/16/23 | 3/28/24 | 3/20/25 | 3/19/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -55.32x | - | - | - | 2.29B | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.04x | 7.96x | 26.09x | 0.05% | 54.57B | |
| 36.97x | 6.56x | 19.6x | 0.88% | 53.59B | |
| 34.86x | 3.39x | 14.64x | -.--% | 45.03B | |
| 48.82x | 5.62x | 30.9x | -.--% | 42.17B | |
| -19.09x | 184.46x | -20.29x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.72x | 5.84x | 15.15x | -.--% | 24.01B | |
| 36.39x | 6.61x | 22.07x | -.--% | 26.5B | |
| Average | 18.67x | 26.11x | 15.76x | 0.34% | 38.56B | |
| Weighted average by Cap. | 26.21x | 24.66x | 15.94x | 0.46% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLS Stock
- Valuation SELLAS Life Sciences Group, Inc.
Select your edition
All financial news and data tailored to specific country editions
